Long COVID Treatment Trial-Tirzepatide (LoCITT-T)

GLMA: Health Professionals Advancing LGBTQ EqualityLong COVID Treatment Trial-Tirzepatide (LoCITT-T)Overview: An estimated 400 million people across the world have Long COVID. So far there has been little research and few effective treatments available. The Long COVID Treatment Trial Tirzepatide (LoCITT-T), sponsored by Scripps Research, will see if a medicine called tirzepatide helps people with Long COVID feel better and could help millions of people living with Long COVID today. Participation can be completed entirely from home, no in-person visits needed.Study Type: Mixed MethodsIRB Approved: YesTarget Audience: Adults (18 years and older), living in the U.S. (excluding Hawaii), documentation of Long COVID diagnosis and other inclusion criteria.How to Apply: Click the linkStudy Contact: LoCITT Study Teamlongcovid-t@scripps.edu1629 K St. NWSuite 300Washington, DC 20006 #J-18808-Ljbffr